Raws li cov ntaub ntawv tshawb fawb soj ntsuam zaum kawg, Tirzepatide feem ntau ua tau zoo dua li Semaglutide hauv kev poob phaus, tab sis kev xaiv ntawm ob yuav tsum tau ua raws li kev xav txog ntawm tus kheej cov xwm txheej.
Cov ntsiab lus tseem ceeb
Tirzepatide qhia tau hais tias zoo tshaj qhov hnyav poob
Lub taub hau - mus rau -Lub taub hau soj ntsuam cov txiaj ntsig (SURMOUNT-5 Txoj Kev Kawm)
Thawj lub taub hau -mus rau- taub hau kev sib piv ntawm Tirzepatide thiab Semaglutide (SURMOUNT-5), luam tawm xyoo 2025, qhia:
| Qhov taw qhia | Tirzepatide | Semaglutide |
| Txhais tau tias poob phaus | -20.2% | -13.7% |
| Txo lub duav ncig | - 18.4 cm | - 13.0 cm |
| Feem pua ntawm cov neeg koom nrog poob phaus Ntau dua lossis sib npaug li 25% | 31.6% | 16.1% |
| Feem pua ntawm cov neeg koom nrog poob phaus Ntau dua lossis sib npaug li 30% | 19.7% | 6.9% |
Txoj kev tshawb no suav nrog 751 rog rog (tsis muaj ntshav qab zib), nrog rau lub sijhawm kho ntawm 72 lub lis piam. Qhov nruab nrab qhov hnyav poob hauv pawg telborpeptide yog 6.5 feem pua cov ntsiab lus ntau dua li ntawm pawg smegglutinin.
Mechanism ntawm Action
| Dimension | Semaglutide | Tirzepatide |
| Mechanism | Tib - phiaj GLP-1 receptor agonist | Dual{0}}target GLP-1/GIP receptor agonist |
| Txoj kev | Activates tsuas yog GLP-1 receptor | Ua kom ob leeg GLP-1 thiab GIP receptors |
| Yam ntxwv | Mature, classic GLP-1 txoj hauv kev |
Dual -lub hom phiaj kev sib koom ua ke, theoretically muaj zog ua tau zoo |
Raws li tus neeg saib xyuas ob lub hom phiaj, tirzepatide muaj cov cuab yeej zoo hauv kev tswj glycemic thiab poob phaus, uas cuam tshuam nws qhov kev ua tau zoo hauv kev sim tshuaj.
Cardiovascular Outcomes
Cov pov thawj muaj zog rau Smegglutide's Cardiovascular Protective Effect
Qhov tiag -kev tshawb fawb thoob ntiaj teb ntawm 21,250 tus neeg mob rog rog / rog uas muaj kab mob plawv (tsis muaj ntshav qab zib) tau qhia tias:
- Piv rau Tirzepatide, Semaglutide tau txuam nrog a29% txonyob rau hauv qhov kev pheej hmoo ntawm peb qhov teeb meem loj ntawm cov hlab plawv (myocardial infarction, stroke, thiab tag nrho- ua rau tuag) (HR 0.71; p=0.046).
- Piv rau Tirzepatide, Semaglutide tau txuam nrog a22% txonyob rau hauv txoj kev pheej hmoo ntawm tsib yam mob plawv tsis zoo (HR 0.78; p=0.040).
Txawm li cas los xij, kev tshaj tawm -hoc kev tshuaj ntsuam ntawm SURMOUNT-5 qhov kev sim qhia tias telpotetide tuaj yeem ua tau zoo dua hauv kev kwv yees qhov txo qis ntawm 10 xyoo ntawm kev pheej hmoo mob plawv. Xav tau kev tshawb fawb ntxiv hauv cheeb tsam no.
Kev nyab xeeb thiab kam rau ua
| Dimension | Semaglutide | Tirzepatide |
| Cov xwm txheej tsis zoo | xeev siab (18%), raws plab (12%), ntuav (8%) | xeev siab (17-22%), raws plab (13-16%), ntuav (6-10%) |
| Discontinuation Rate Vim AEs | 5.6% hauv SURMOUNT-5 | 2.7% hauv SURMOUNT-5 |
| Kev Kho Mob Dose Achievement Rate (Real{0}}World) | 52.9% mus txog kev noj tshuaj | 77.6% mus txog kev noj tshuaj |
| Lub Sijhawm Saib Xyuas Kev Kho Mob | Nruab nrab 143 hnub | Nruab nrab 32 hnub |
Nrhiav qhov tseem ceeb: Tiag -cov kev tshawb fawb hauv ntiaj teb qhia tias txawm hais tias tirzepatide muaj qhov tshwm sim ntau dua ntawm cov xwm txheej hauv plab hnyuv, nws qhov kev txiav txim siab tsis tu ncua vim qhov tshwm sim tsis zoo yog qhov qis dua. Qhov no tej zaum yuav muaj feem xyuam nrog kev noj tshuaj ntau dua - kev nce ntxiv nrog tirzepatide.
Qhov tseem ceeb sib txawv hauv kev xyaum
Dose Elevation Experience
Qhov no yog ib qho tseem ceeb tab sis yooj yim overlooked qhov sib txawv ntawm ob cov tshuaj hauv kev siv tiag tiag:
Tirzepatide: 77.6% ntawm cov neeg mob ua tiav kev nce qib kom ncav cuag lub hom phiaj kev noj tshuaj, nrog lub sijhawm nruab nrab ntawm tsuas yog 32 hnub.
Semaglutide: Tsuas yog 52.9% ntawm cov neeg mob ncav cuag cov tshuaj noj, nrog lub sijhawm nruab nrab ntev li 143 hnub.
Qhov no txhais tau hais tias hauv kev kho mob tiag tiag, cov neeg mob siv Tirzepatide feem ntau yuav ua raws li "cov koob tshuaj zoo," thaum ze li ib nrab ntawm cov neeg mob Semaglutide tsis ua tiav koob tshuaj nce ntxiv rau ntau yam laj thawj.
Cov lus pom zoo xaiv
| Yog koj qhov xwm txheej yog | Pom zoo xaiv |
| Ua raws li qhov hnyav tshaj plaws | Tirzepatide(kev poob phaus ntau dua, kwv yees li 6-7% ntxiv lub cev hnyav txo) |
| Xav tau kev pib sai sai | Tirzepatide(Smoother dose escalation, shorter time to maintenance dose) |
| Sensitive rau gastrointestinal teebmeem | Ob leeg xav tau kev saib xyuas, tab sis tirzepatide tej zaum yuav zoo dua vim qhov txo qis dua |
| Nyiam cov tshuaj uas muaj cov ntaub ntawv kho mob paub ntau dua | Semaglutide(Lub sijhawm ntev ntawm kev ua lag luam, ntau cov ntaub ntawv pov thawj ntau dua) |
| Kho obstructive pw tsaug zog apnea | Tirzepatide(Qhov no qhia tau pom zoo) |
Cov ntsiab lus
Tirzepatide yog qhov kev xaiv poob phaus zoo dua: Lub taub hau - mus rau - lub taub hau kev sim tshuaj pom tau tias Tirzepatide ua rau kwv yees li 6.5% ntau qhov poob phaus (qhov sib txawv kiag li) dua li smegglutide, sawv cev qhov hnyav nce ntawm kwv yees li 50%.
Ob leeg muab kev tiv thaiv kab mob plawv zoo sib xws: Loj- nplai tiag- cov pov thawj hauv ntiaj teb tau tshaj tawm hauv Nature Medicine (2026) tau pom tias qhov kev phom sij rau qhov kawg ntawm myocardial infarction, mob stroke, lossis tag nrho- ua rau kev tuag yog 1.06 (95% CI: 0.95-1.18), qhia qhov sib txawv tseem ceeb. Rau cov neeg mob uas nws qhov kev txhawj xeeb tseem ceeb yog txo qis kev pheej hmoo ntawm cov hlab plawv, tus neeg sawv cev tuaj yeem muab kev tiv thaiv zoo.
Tirzepatide sib txawv yuav tsum tau xav txog tus kheej: Txawm tias Tirzepatide muaj cov kev mob tshwm sim ntawm plab hnyuv me ntsis, nws qhov kev txiav tawm qis dua, uas yuav cuam tshuam nrog kev paub zoo dua nrog kev nce koob tshuaj.
Kev txiav txim siab tseem ceeb- ua yam tseem ceeb: Yog tias lub hom phiaj yog txhawm rau kom poob phaus, tirzepatide yog qhov kev xaiv zoo dua; Yog tias cov ntaub ntawv kho mob paub tab ntau dua, lossis yog tias muaj cov contraindications tshwj xeeb, semaglutide tseem yog qhov kev xaiv txhim khu kev qha.Rau cov neeg mob uas muaj obstructive pw tsaug zog apnea, tirzepatide tuav ib tug tshwj xeeb kom zoo dua raws li nws yog thawj thiab tsuas yog GIP / GLP-1 dual agonist pom zoo rau qhov qhia no. Thaum kawg, kev xaiv yuav tsum tau koom tes nrog tus kws kho mob raws li cov hom phiaj kev kho mob ntawm tus kheej, keeb kwm kev kho mob, thiab kev tiv thaiv kab mob.
Lus Cim Tseem Ceeb: Cov ntaub ntawv saum toj no yog ua raws cov pov thawj -raws li kev tshawb fawb tshuaj. Kev xaiv tshuaj tshwj xeeb yuav tsum tau txiav txim siab los ntawm ib tus kws kho mob tshwj xeeb raws li kev ntsuam xyuas dav dav ntawm koj tus kheej tus mob, keeb kwm tshuaj, contraindications, thiab lwm yam. Tsis txhob tus kheej - kho lossis hloov tshuaj.
